Nivolumab + Relatlimab (PD-1/LAG-3) Adds 10% Absolute 5-Year OS in 1L Melanoma

Nivolumab is a PD-1 inhibitor and relatlimab is a LAG-3 inhibitor evaluated as a fixed-dose combination versus nivolumab alone in the randomized, double-blind Phase 3 RELATIVITY-047 first-line trial in unresectable/metastatic melanoma (n=714; NCT03470922). At 57.3 months minimum follow-up, nivolumab+relatlimab improved median PFS to 10.2 vs 4.6 months (HR 0.77) and median OS to 54.8 vs 33.2 months (HR 0.78), with 60-month OS 48% vs 38% and ORR 44% vs 34%. Grade 3–4 TRAEs were higher than nivolumab alone (23% vs 12%; TRAE discontinuation 17% vs 10%) but below historical nivolumab+ipilimumab toxicity, where grade 3–4 TRAEs are roughly 55%.